Description of Research Expertise

A major focus in the Andrabi laboratory is to utilize in vitro directed evolution platform combined with structure-guided design approaches to develop vaccine immunogens against complex pathogens such as HIV, Influenza virus, Arenaviruses and Coronaviruses. The other major area of research in his laboratory is to understand the immunological basis of B cell affinity maturation pathways to complex antigen surfaces, both in vaccination and in infection and to utilize this information for designing more effective vaccines. The overall goal is to design vaccine immunogens and immunization strategies that can induce protective broadly neutralizing antibody responses against complex pathogens through vaccination in humans.

Selected Publications

Kaku CI, Starr TN, Zhou P, Dugan HL, Khalifé P, Song G, Champney ER, Mielcarz DW, Geoghegan JC, Burton DR, Andrabi R, Bloom JD, Walker LM: Evolution of antibody immunity following Omicron BA.1 breakthrough infection. Nat Commun 14 (1): 2751,2023.

Song G, Yuan M, Liu H, Capozzola T, Lin RN, Torres JL, He W-t, Musharrafieh R, Dueker K, Zhou P, Callaghan S, Mishra N, Yong P, Anzanello F, Avillion G, Vo AL, Li X, Makhdoomi M, Feng Z, Zhu X, Peng L, Nemazee D, Safonova Y, Briney B, Ward AB, Burton DR#, Wilson IA#, Andrabi R.: Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift bioRxiv 9 (13): 557606,2023.

Tan TJC, Mou Z, Lei R, Ouyang WO, Yuan M, Song G, Andrabi R, Wilson IA, Kieffer C, Dai X, Matreyek KA, Wu NC.: High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike Nat Commun 14 (1): eprint,2023.

Zhou P, Song G, He WT, Beutler N, Tse LV, Martinez DR, Schr A, Anzanello F, Yong P, Peng L, Dueker K, Musharrafieh R, Callaghan S, Capozzola T, Yuan M, Liu H, Limbo O, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Jardine JG, Wilson IA, Safonova Y, Rogers TF, Baric RS, Gralinski LE, Burton DR, Andrabi R.: Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease Immunity 56 (3): 669–686,2023.

Dadonaite B, Crawford KHD, Radford CE, Farrell AG, Yu TC, Hannon WW, Zhou P, Andrabi R, Burton DR, Liu L, Ho DD, Chu HY, Neher RA, Bloom JD: A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. Cell 186 (6): 1263-1278.e20,2023.

Allen JD, Ivory D, Song SG, He W-t, Capozzola T, Yong P, Burton DR, Andrabi R, Crispin M: The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2. Cell Reports 25 (4): 112307,2023.

Bibollet-Ruche F, Russell RM, Ding W, Liu W, Li Y, Wagh K, Wrapp D, Habib R, Skelly AN, Roark RS, Sherrill-Mix S, Wang S, Rando J, Lindemuth E, Cruickshank K, Park Y, Baum R, Carey JW, Connell AJ, Li H, Giorgi EE, Song GS, Ding S, Finzi A, Newman A, Hernandez GE, Machiele E, Cain DW, Mansouri K, Lewis MG, Montefiori DC, Wiehe KJ, Alam SM, Teng IT, Kwong PD, Andrabi R, Verkoczy L, Burton DR, Korber BT, Saunders KO, Haynes BF, Edwards RJ, Shaw GM, Hahn BH.: A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies mBio 14 (1): e0337022,2023.

Bibollet-Ruche F, Russell RM, Ding W, Liu W, Li Y, Wagh K, Wrapp D, Habib R, Skelly AN, Roark RS, Sherrill-Mix S, Wang S, Rando J, Lindemuth E, Cruickshank K, Park Y, Baum R, Connell A, Li H, Giorgi EE, Song GS, Ding S, Finzi A, Newman A, Hernandez GE, Machiele E, Cain DW, Mansouri K, Lewis MG, Montefiori DC, Wiehe KJ, Alam SM, Teng I-T, Kwong PD, Andrabi R, Verkoczy L, Burton DR, Korber BT, Saunders KO, Haynes BF, Edwards RJ, Shaw GM, Hahn BH.: A germline-targeting chimpanzee SIV envelope glycoprotein elicits a new class of V2-apex directed cross-neutralizing antibodies. mBio 14 (1): e03370-22,2023.

Choudhary A, Calianese D, Honnen W, Kolloli A, Dikdan RJ, Jaijyan D, Song G, Capozzola T, Sy C, Akkaraju V, Mattappallil A, Rosania A, Khan S, Lerman M, Nikaein A, Subbian S, Chou T-C, Andrabi R, Burton D, Pinter A.: “Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B.1 to BQ.1.1.” bioRxiv : 2023.

Hurtado J, Rogers TF, Jaffe DB, Adams B, Bangaru S, Garcia E, Capozzola T, Messmer T, Sharma P, Song G, Beutler N, He W, Dueker K, Musharrafieh R, Stubbington MTJ, Burton D, Andrabi R, Ward A, McDonnell WJ, Briney B.: Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple epitopes bioRxiv : 2023.

View all publications

Academic Contact Information

Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
506-A Johnson Pavilion
3610 Hamilton Walk

Philadelphia, PA 19104
Phone: 774-641-0735